

INVESTOR FACT SHEET

AT-A-GLANCE

Skystar is a leading manufacturer and distributor of veterinary medicines and healthcare products in China. Supplying both Traditional Chinese Medicine (TCM) and Western Medicine; the Company provides a comprehensive suite of veterinary products serving regional micro-farms offering:

- Veterinary vaccines
- Veterinary medicines
- Pro-biotic microorganisms
- Animal feed additives
- *Aquaculture vaccines to come online fiscal 2010


Headquartered in Xi'an, Shaanxi Province, Central China, Skystar is the only US-listed pure play in the China animal health sector. Skystar's China GMP certified production facilities and processes is regulated by China's State Food and Drug Administration (SFDA) under China's Ministry of Health.

200+ employees (including representatives in the U.S.)

INVESTMENT HIGHLIGHTS

- Only U.S. listed China pure-play in the veterinary health sector
- Strong financial position and historical performance
- Proven track record for growing the Company profitably
- Positioned to take advantage of China's changing dietary needs
- Potential industry consolidator in a fragmented market
- Government is supportive of free markets in this industry
- Expansive sales and distribution network across all 29 farm producing provinces in China

REVENUES BY OFFERING (200+ products)



- PRODUCT MARGINS AVERAGE 51% -

DISTRIBUTION CHANNEL

Unmatched distribution channel:


- 1,464 distribution agents
- 518 direct customers
- 350 franchised stores with exclusivity agreements
- Serving all 29 farm provinces of China



GROWTH STRATEGY

- Skystar's dedicated R&D facilities introduced 42 new products in 2009; 40 in 2010
- Facilities expansion completed in 2010
 - Micro-organism production by 49%
 - Vaccine production to come online in fiscal 2010
- Acquired rights to produce aquaculture vaccine through 2025
 - Annual revenues of \$8M-\$15M in 3-5 years
- Seeking acquisitions with the potential to be near term accretive

HISTORICAL REVENUE



MANAGEMENT

Weibing Lu - Chairman and CEO

Michael Lan - Chief Financial Officer

Scott Cramer - Director Corporate Development and U.S. Rep.

CONTACT INFO:

Skystar Headquarters (China)

Rm. 10601, Jiezu Plaza, No. 4, Fenghui Road South, Gaoxin District, Xi'an, Shaanxi Province, P.R.China

T: +86 (29) 8819-3188

Director Corporate Development and U.S. Representative

Scott Cramer, Director

T: + 1 (407) 645-4433

E: scramer@skystarbio-pharmaceutical.com

Investor Relations

Grayling

Christopher Chu, Director

825 Third Avenue, 18th Floor, New York, NY 10022

T: +1 (646) 284-9426 | Website: www.grayling.com

